Xingping Su
Sichuan University(CN)State Key Laboratory of Biotherapy
Publications by Year
Research Areas
Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis, Sarcoidosis and Beryllium Toxicity Research, Fibroblast Growth Factor Research, Peptidase Inhibition and Analysis, Cancer Mechanisms and Therapy
Most-Cited Works
- → Design and Synthesis of EZH2-Based PROTACs to Degrade the PRC2 Complex for Targeting the Noncatalytic Activity of EZH2(2021)115 cited
- → Repurposing of the anti-helminthic drug niclosamide to treat melanoma and pulmonary metastasis via the STAT3 signaling pathway(2019)41 cited
- → Application and Study of ROCK Inhibitors in Pulmonary Fibrosis: Recent Developments and Future Perspectives(2023)31 cited
- → Dopaminylation of endothelial TPI1 suppresses ferroptotic angiocrine signals to promote lung regeneration over fibrosis(2024)28 cited
- → A novel multikinase inhibitor SKLB‐YTH‐60 ameliorates inflammation and fibrosis in bleomycin‐induced lung fibrosis mouse models(2021)28 cited
- → Matrix metalloproteinases inhibitors in idiopathic pulmonary fibrosis: Medicinal chemistry perspectives(2021)22 cited
- → Synthesis and biological evaluation of indazole derivatives as anti-cancer agents(2021)21 cited
- → An oral phenylacrylic acid derivative suppressed hepatic stellate cell activation and ameliorated liver fibrosis by blocking TGF‐β1 signalling(2022)12 cited
- → Discovery and evaluation of phenacrylanilide derivatives as novel potential anti-liver fibrosis agents(2022)9 cited
- → Discovery of the novel Benzo[b]thiophene 1,1-dioxide derivatives as a potent STAT3 inhibitor against idiopathic pulmonary fibrosis(2022)9 cited